Matches in SemOpenAlex for { <https://semopenalex.org/work/W2889668007> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2889668007 endingPage "2219" @default.
- W2889668007 startingPage "2219" @default.
- W2889668007 abstract "2219 Patient derived tumor models established sc in nude mice have been shown to predict well the response of standard and novel agents compared with clinic activity. In 80 comparisons we have treated the same tumor in the patient and in the nude mouse. In 21 cases the tumor went into remission in the patient and the same response were seen in 19 cases in the nude mouse (90%). When no response was seen in 59 patients the same result was observed in the nude mouse in 57 tumors giving a correct prediction of the xenograft model of 97%. The combination of cytotoxic agents with novel signal transduction inhibitors improved the time to progression and survival time in patients with colorectal (chemo plus Avastin or Cetuximab), non-small cell lung (Avastin) and breast cancers (combo with Herceptin or Avastin). In order to identify suitable xenograft models for such combination studies we investigated the effect of 5FU, Capecitabin, CPT-11 and Oxaliplatin. Treatment started when the sc implanted tumors reached tumor volumes around 5 - 7 mm (about 100 mm³). The compounds where given at their MTD (around LD20 after 2 cycles): 5FU at 100 mg/kg/d ip day 1, 8, 15, Capecitabin 300 mg/kg/d po day 1 to 10 - 14, CPT11 75 mg/kg/d iv day 1 and 8 as well as Oxaliplatin 8 mg/kg day 1,15 ip. All 4 compounds showed high activity mainly in colorectal, mammary and in non-small lung cancer. Capecitabin effected inhibition Overall the activity pattern in the engraft system resembles the activity in the clinic. Suitable models with a moderate sensitivity against the single agent therapy are being selected for combining two-drug cytostatic combinations with Avastin, Cetuximab, and other new signal transduction inhibitors." @default.
- W2889668007 created "2018-09-27" @default.
- W2889668007 creator A5005150806 @default.
- W2889668007 creator A5028821954 @default.
- W2889668007 creator A5034493142 @default.
- W2889668007 creator A5065212894 @default.
- W2889668007 creator A5076633419 @default.
- W2889668007 date "2007-05-01" @default.
- W2889668007 modified "2023-09-23" @default.
- W2889668007 title "Chemosensitivity of patient derived human tumor xenograft models against 5FU, Capecitabin, CPT-11 and Oxaliplatin" @default.
- W2889668007 hasPublicationYear "2007" @default.
- W2889668007 type Work @default.
- W2889668007 sameAs 2889668007 @default.
- W2889668007 citedByCount "0" @default.
- W2889668007 crossrefType "journal-article" @default.
- W2889668007 hasAuthorship W2889668007A5005150806 @default.
- W2889668007 hasAuthorship W2889668007A5028821954 @default.
- W2889668007 hasAuthorship W2889668007A5034493142 @default.
- W2889668007 hasAuthorship W2889668007A5065212894 @default.
- W2889668007 hasAuthorship W2889668007A5076633419 @default.
- W2889668007 hasConcept C121608353 @default.
- W2889668007 hasConcept C126322002 @default.
- W2889668007 hasConcept C143998085 @default.
- W2889668007 hasConcept C2779998722 @default.
- W2889668007 hasConcept C2780278673 @default.
- W2889668007 hasConcept C2780962732 @default.
- W2889668007 hasConcept C502942594 @default.
- W2889668007 hasConcept C526805850 @default.
- W2889668007 hasConcept C71924100 @default.
- W2889668007 hasConceptScore W2889668007C121608353 @default.
- W2889668007 hasConceptScore W2889668007C126322002 @default.
- W2889668007 hasConceptScore W2889668007C143998085 @default.
- W2889668007 hasConceptScore W2889668007C2779998722 @default.
- W2889668007 hasConceptScore W2889668007C2780278673 @default.
- W2889668007 hasConceptScore W2889668007C2780962732 @default.
- W2889668007 hasConceptScore W2889668007C502942594 @default.
- W2889668007 hasConceptScore W2889668007C526805850 @default.
- W2889668007 hasConceptScore W2889668007C71924100 @default.
- W2889668007 hasLocation W28896680071 @default.
- W2889668007 hasOpenAccess W2889668007 @default.
- W2889668007 hasPrimaryLocation W28896680071 @default.
- W2889668007 hasRelatedWork W1949863012 @default.
- W2889668007 hasRelatedWork W1995034071 @default.
- W2889668007 hasRelatedWork W2059783345 @default.
- W2889668007 hasRelatedWork W2125337286 @default.
- W2889668007 hasRelatedWork W2253512731 @default.
- W2889668007 hasRelatedWork W2255135986 @default.
- W2889668007 hasRelatedWork W2419091182 @default.
- W2889668007 hasRelatedWork W2422708734 @default.
- W2889668007 hasRelatedWork W2434990928 @default.
- W2889668007 hasRelatedWork W2558827509 @default.
- W2889668007 hasRelatedWork W2611689931 @default.
- W2889668007 hasRelatedWork W2761493034 @default.
- W2889668007 hasRelatedWork W2788773988 @default.
- W2889668007 hasRelatedWork W2789506011 @default.
- W2889668007 hasRelatedWork W2793829784 @default.
- W2889668007 hasRelatedWork W2925211384 @default.
- W2889668007 hasRelatedWork W293608685 @default.
- W2889668007 hasRelatedWork W3164912862 @default.
- W2889668007 hasRelatedWork W571862978 @default.
- W2889668007 hasRelatedWork W2754946310 @default.
- W2889668007 hasVolume "67" @default.
- W2889668007 isParatext "false" @default.
- W2889668007 isRetracted "false" @default.
- W2889668007 magId "2889668007" @default.
- W2889668007 workType "article" @default.